$BCDA

4 stories mentioning BCDA

Every FINWIRES story that references BCDA, newest first.

Sector Update: Healthcare Stocks Higher Late Afternoon

Healthcare stocks rose late Friday afternoon with the NYSE Healthcare Index increasing 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.7%.The iShares Biotechnology ETF (IBB) declined 1.6%.In corporate news, Haemonetics (HAE) updated its financial reporting structure and will transition to two segments from three starting in Q1 fiscal 2027. The stock rose 1.8%.BioCardia (BCDA) received confirmation from the US Food and Drug Administration that its ongoing trial may support a premarket approval of the CardiAMP Cell Therapy System for the treatment of ischemic heart failure with reduced ejection fraction. BioCardia shares climbed 23%.CareCloud (CCLD) said shareholders approved all proposals put forward at the annual investor meeting on Thursday, including the re-election of Mahmud Haq and Cameron Munter to the board. CareCloud shares fell 1.5%.Vivos Therapeutics (VVOS) entered a deal with its senior secured lender, Streeterville Capital, to exchange up to $4.5 million of its outstanding debt for a combination of perpetual, nonconvertible preferred stock and shares. Vivos shares climbed 27%.

$BCDA$CCLD$HAE$VVOS

Sectors9d ago

Sector Update: Healthcare Stocks Gain Friday Afternoon

Healthcare stocks rose Friday afternoon, with the NYSE Healthcare Index increasing 1.2% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.3%.The iShares Biotechnology ETF (IBB) declined 1%.In corporate news, Teva Pharmaceutical Industries' (TEVA) Teva Pharmaceuticals unit said Friday that a real-world study shows Austedo and Austedo XR tablets improved quality of life for Huntington's disease chorea patients and their caregivers. Teva Pharmaceutical shares were up 0.8%.BioCardia (BCDA) said it has received confirmation from the US Food and Drug Administration that its ongoing heart failure trial may support a premarket approval of the CardiAMP Cell Therapy System for the treatment of ischemic heart failure with reduced ejection fraction. BioCardia shares climbed more than 24%.Edesa Biotech (EDSA) said Friday that new data showed that paridiprubart combined with standard of care treatments was associated with a 32% relative reduction in mortality in patients with acute kidney injury and respiratory distress at 28 days. Edesa Biotech shares dropped 22.4%.

$BCDA$EDSA$TEVA

Wire9d ago

Top Midday Gainers

Solidion Technology (STI) patented a lithium anode protection technology that paves the way for full-scale commercialization of lithium-sulfur, lithium-air, and anodeless lithium metal batteries, it said early Friday.Shares jumped 31% amid a surge in intraday trading volume to over 29.9 million from a daily average of roughly 68,000.Concrete Pumping (BBCP) reported fiscal Q2 earnings and revenue above market expectations, and raised its full-year fiscal 2026 sales forecast, according to its earnings statement late Thursday.Shares climbed 31% following an increase in intraday trading volume to about 3.7 million from a daily average of 133,000.BioCardia (BCDA) received confirmation from the US Food and Drug Administration that its ongoing heart failure trial may support a premarket approval of the CardiAMP Cell Therapy System for the treatment of ischemic heart failure with reduced ejection fraction, the company said.Shares advanced 26% as intraday trading volume catapulted to over 138.6 million from a daily average of about 164,000.Price: $1.21, Change: $+0.29, Percent Change: +31.77%

$BBCP$BCDA$STI

Sectors10d ago

Sector Update: Healthcare Stocks Rise Premarket Friday

Healthcare stocks were rising premarket Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) advancing by 0.7% and the iShares Biotechnology ETF (IBB) 0.3% higher.Amneal Pharmaceuticals (AMRX) stock was up more than 2% after the company said interim results from its phase 4 study of Crexont to treat Parkinson's disease demonstrated substantial clinical benefit after patients switched to the drug from Rytary.BioCardia (BCDA) has received confirmation from the US Food and Drug Administration that its ongoing heart failure trial may support a premarket approval of the CardiAMP Cell Therapy System for the treatment of ischemic heart failure with reduced ejection fraction, the company said. Shares of BioCardia were up more than 33% pre-bell.

$AMRX$BCDA$IBB$XLV